High expression of BIRC5 is associated with poor prognosis in patients with hepatocellular and pancreatic cancer, lung cancer, renal papillary cell carcinoma, renal clear cell carcinoma, endometrial carcinoma, and sarcoma. Here, BIRC5 is linked to sarcoma.